A5103136454- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Cancer Diagnosis and Treatment
- Cancer-related cognitive impairment studies
- Medical Imaging and Pathology Studies
- Lung Cancer Diagnosis and Treatment
- Chemotherapy-related skin toxicity
- Metastasis and carcinoma case studies
- Gastric Cancer Management and Outcomes
- Neutropenia and Cancer Infections
- Multiple and Secondary Primary Cancers
- Frailty in Older Adults
- Biosimilars and Bioanalytical Methods
- Melanoma and MAPK Pathways
- HER2/EGFR in Cancer Research
Carlo Forlanini Hospital
2004-2021
Ospedale generale di zona San Camillo Treviso
2010-2021
Università della Svizzera italiana
2009
Marche Polytechnic University
2009
IRCCS San Camillo Hospital
2009
Ospedale di Livorno
2009
Ospedale degli Infermi
2007
Azienda Ospedaliera Treviglio
2007
Institute of Oncology Research
2006
Sapienza University of Rome
2002-2004
Abstract We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence metastasis were collected statistically analyzed. Bone metastases evident at diagnosis 57.5% patients. In remaining cases median time appearance was 9 months. Biphosphonates administered 59.6% Skeletal-related events experienced by...
Cisplatin, a standard component of combination chemotherapy for several tumors, presents important anti-tumor properties but also toxic effects. In particular, the major dose-limiting effect appears to be renal toxicity. countries, reduce nephrotoxicity after cisplatin administration, 24-h hydration is recommended following treatment in hospital regimen. our Institutions, an outpatient that provides adequate with NaCl solution plus furosemide and diuresis monitoring during treatment.To...
Study Type – Therapy (individual cohort) Level of Evidence 2b What's known on the subject? and What does study add? Sorafenib is an oral receptor tyrosine kinase inhibitor that inhibits RAF serine/threonine kinases (vascular endothelial growth factor receptors 1, 2, 3 platelet‐derived factor‐beta, Flt‐3 c‐kit) are implicated in tumourigenesis tumour progression. approved for treatment advanced renal cell cancer. B‐RAF mutations (V600E K601E) may be interesting negative predictive markers...
e16027 Background: Sorafenib is an orally active multikinase inhibitor (Raf kinase, VEGFR 1, 2, 3 and PDGFR inhibitor) for the treatment of advanced RCC. The purpose this study was to assess efficacy toxicity in mRCC patients (pts) previously treated with anti-angiogenic VEGFR-TKI using escalating dose levels. Methods: Pts mRCC, PS 0–2 adequate organ function were eligible. received 400 mg/BID/continuously 4-wk cycles. no progressive disease (evaluated at 12 weeks) continued receive standard...
A 46-year-old woman had an episode of atrial fibrillation during infusion docetaxel as adjuvant chemotherapy for infiltrating ductal carcinoma the breast. All cardiological tests performed before treatment were normal and there was no evidence thyroid dysfunction nor any objective or anamnestic data indicating acute chronic cardiovascular disease. None drugs administered has ever shown proarrhythmic activity. In controlled clinical trials found to have a very low cardiotoxicity.
// Alessandra Ulivieri 1, 2 , Giuseppe Cardillo 3 Liborio Manente 1 Gregorino Paone 4 Andrea Petricca Mancuso 5 Leonardo Vigna Enrico Di Stasio 6 Rita Gasbarra Salvatore Girlando 7 Alvaro Leone Anatomic Pathology Unit, San Camillo-Forlanini Hospitals, Rome, Italy Laboratory of Biomedical research “Fondazione Niccolò Cusano per la Ricerca Medico-Scientifica” University Thoracic Surgery Department Respiratory Diseases, Medical Oncology, Institute Biochemistry and Clinical...
Objectives: The discovery of tyrosine kinase inhibitors (TKI) has remarkably improved the clinical course patients with non–small cell lung cancer driven by Epidermal Growth Factor Receptor ( EGFR ) mutations. However, virtually in all cases, disease resurfaces a TKI-resistant form that is mainly linked to an acquired -T790M mutation, MET amplification, or small (SCLC) transformation. Third-generation TKIs are able block tumor growth through irreversible binding T790M-mutated receptor. Such...